Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

Background Mutant isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) enzymes produce the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a targeted mutant IDH1 inhibitor under evaluation in a phase 1 dose escalation and expansion study of IDH1-mutant advanced solid tumors including chol...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Bin, Mellinghoff, Ingo K., Wen, Patrick Y., Lowery, Maeve A., Goyal, Lipika, Tap, William D., Pandya, Shuchi S., Manyak, Erika, Jiang, Liewen, Liu, Guowen, Nimkar, Tara, Gliser, Camelia, Prahl Judge, Molly, Agresta, Sam, Yang, Hua, Dai, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066280/
https://www.ncbi.nlm.nih.gov/pubmed/31028664
http://dx.doi.org/10.1007/s10637-019-00771-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066280/
https://www.ncbi.nlm.nih.gov/pubmed/31028664
http://dx.doi.org/10.1007/s10637-019-00771-x

Ejemplares similares